SEC Comment Letter 0000000000-25-003600 to Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: April 3, 2025 · CIK: 0001642380 · Accession: 0000000000-25-003600
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286251
Letter
Re: Oncocyte Corporation Registration Statement on Form S-1 Filed March 28, 2025 File No. 333-286251 Dear Joshua Riggs:
April 3, 2025
Joshua Riggs President and Chief Executive Officer Oncocyte Corporation 15 Cushing Irvine, CA 92618
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Greg Kramer, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 3, 2025 Joshua Riggs President and Chief Executive Officer Oncocyte Corporation 15 Cushing Irvine, CA 92618 Re: Oncocyte Corporation Registration Statement on Form S-1 Filed March 28, 2025 File No. 333-286251 Dear Joshua Riggs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Greg Kramer, Esq. </TEXT> </DOCUMENT>